VIM and colitis: We showed here that the loss of vimentin in vivo leads to susceptibility to develop colitis-associated CRC upon the combination of AOM carcinogen treatment and DSS inflammatory injury, whereas the deletion of vimentin alone does not predispose to colitis-associated CRC (Figure 5).